These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17545461)

  • 1. Avoiding mistakes in calculating the number needed to treat in severe COPD.
    Aaron SD
    Am J Respir Crit Care Med; 2007 Jun; 175(12):1347; author reply 1347-8. PubMed ID: 17545461
    [No Abstract]   [Full Text] [Related]  

  • 2. Do we need three players in COPD treatment?
    Maestrelli P; Mason P; Costa F; Paggiaro P
    Respiration; 2013; 86(4):275-6. PubMed ID: 23988429
    [No Abstract]   [Full Text] [Related]  

  • 3. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for chronic obstructive pulmonary disease: possible confounding effect of treatment withdrawal?
    Brown SM
    Ann Intern Med; 2007 Dec; 147(12):882; author reply 882-3. PubMed ID: 18087061
    [No Abstract]   [Full Text] [Related]  

  • 4. Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?
    Gillissen A
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105; author reply 106-7. PubMed ID: 18565963
    [No Abstract]   [Full Text] [Related]  

  • 5. Hospitalizations with severe COPD.
    Oba Y
    Am J Respir Crit Care Med; 2007 Jun; 175(11):1207; author reply 1207-8. PubMed ID: 17519347
    [No Abstract]   [Full Text] [Related]  

  • 6. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease.
    Lee JS; Huh JW; Chae EJ; Seo JB; Ra SW; Lee JH; Kim EK; Lee YK; Kim TH; Kim WJ; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Sheen SS; Oh YM; Lee SD
    J Korean Med Sci; 2011 Mar; 26(3):379-85. PubMed ID: 21394306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P
    MMW Fortschr Med; 2003 Jun; 145(24):20. PubMed ID: 12866294
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of pharmacotherapy on rate of decline of FEV(1) in the TORCH study.
    Marchand E
    Am J Respir Crit Care Med; 2009 Mar; 179(5):426; author reply 426-7. PubMed ID: 19234322
    [No Abstract]   [Full Text] [Related]  

  • 10. Combined salmeterol and fluticasone for COPD.
    Vassiliou V
    Lancet; 2003 May; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract]   [Full Text] [Related]  

  • 11. Summaries for patients. Combination inhaler therapy for chronic obstructive pulmonary disease.
    Ann Intern Med; 2007 Apr; 146(8):I12. PubMed ID: 17310044
    [No Abstract]   [Full Text] [Related]  

  • 12. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.
    Vestbo J; Soriano JB; Anderson JA; Calverley P; Pauwels R; Jones P;
    Respir Med; 2004 Nov; 98(11):1045-50. PubMed ID: 15526804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB; Tillie-Leblond I; Attali V; Bavelele Z; Lagrange O
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
    Fenton C; Keating GM
    Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment step down should be avoided at entry in COPD therapeutic trials.
    Marchand E
    Am J Respir Crit Care Med; 2008 Jul; 178(1):105-6; author reply 106-7. PubMed ID: 18565962
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.